drugset / Trial / NCT03371719

Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial

NCT03371719

Phase 2 Active not recruiting 298 enrolled NRG Oncology National Cancer Institute (NCI) · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This phase II trial studies how well radiation therapy with or without apalutamide works in treating patients with prostate cancer that has come back (recurrent). Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgen can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may lessen the amount of androgen made by the body. Giving radiation therapy and apalutamide may work better at treating prostate cancer compared to radiation therapy alone.

Timeline

Start
2018-06-20
Primary completion
2025-03-10
Completion
2026-10-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Apalutamide Small molecule Oral